Selected research
Market Structure
Global Hepatitis B Vaccine (Recombinant) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Hepatitis B Vaccine (Recombinant) market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Hepatitis B Vaccine (Recombinant) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Hepatitis B Vaccine (Recombinant) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Hepatitis B Vaccine (Recombinant) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Hepatitis B Vaccine (Recombinant) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Hepatitis B Vaccine (Recombinant) include GSK, Shenzhen Kangtai Biological Products, Merck, Serum Institute, Sanofi Pasteur, LG Life Sciences, KM Biologics and Dynavax Technologies, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Hepatitis B Vaccine (Recombinant) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Hepatitis B Vaccine (Recombinant) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Hepatitis B Vaccine (Recombinant) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hepatitis B Vaccine (Recombinant) market size, projected growth trends, production technologies, key applications, and end-use industries.
Hepatitis B Vaccine (Recombinant) Segment by Company
GSK
Shenzhen Kangtai Biological Products
Merck
Serum Institute
Sanofi Pasteur
LG Life Sciences
KM Biologics
Dynavax Technologies
Hepatitis B Vaccine (Recombinant) Segment by Type
10mcg/0.5ml
10mcg/ml
Hepatitis B Vaccine (Recombinant) Segment by Application
Newborn
Adult
Hepatitis B Vaccine (Recombinant) Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatitis B Vaccine (Recombinant) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hepatitis B Vaccine (Recombinant) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatitis B Vaccine (Recombinant).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Hepatitis B Vaccine (Recombinant) market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hepatitis B Vaccine (Recombinant) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Hepatitis B Vaccine (Recombinant) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Hepatitis B Vaccine (Recombinant) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- 10mcg/0.5ml
- 10mcg/ml
Applications
- Newborn
- Adult
Companies covered
- GSK
- Shenzhen Kangtai Biological Products
- Merck
- Serum Institute
- Sanofi Pasteur
- LG Life Sciences
- KM Biologics
- Dynavax Technologies
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Hepatitis B Vaccine (Recombinant) Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Hepatitis B Vaccine (Recombinant) Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Hepatitis B Vaccine (Recombinant) Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Hepatitis B Vaccine (Recombinant) Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Hepatitis B Vaccine (Recombinant) Market Dynamics
- 2.1 Hepatitis B Vaccine (Recombinant) Industry Trends
- 2.2 Hepatitis B Vaccine (Recombinant) Industry Drivers
- 2.3 Hepatitis B Vaccine (Recombinant) Industry Opportunities and Challenges
- 2.4 Hepatitis B Vaccine (Recombinant) Industry Restraints
3 Hepatitis B Vaccine (Recombinant) Market by Manufacturers
- 3.1 Global Hepatitis B Vaccine (Recombinant) Revenue by Manufacturers (2021-2026)
- 3.2 Global Hepatitis B Vaccine (Recombinant) Sales by Manufacturers (2021-2026)
- 3.3 Global Hepatitis B Vaccine (Recombinant) Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Hepatitis B Vaccine (Recombinant) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Hepatitis B Vaccine (Recombinant) Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Hepatitis B Vaccine (Recombinant) Manufacturers, Product Type & Application
- 3.7 Global Hepatitis B Vaccine (Recombinant) Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Hepatitis B Vaccine (Recombinant) Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Hepatitis B Vaccine (Recombinant) Players Market Share by Revenue in 2025
- 3.8.3 2025 Hepatitis B Vaccine (Recombinant) Tier 1, Tier 2, and Tier 3
4 Hepatitis B Vaccine (Recombinant) Market by Type
- 4.1 Hepatitis B Vaccine (Recombinant) Type Introduction
- 4.1.1 10mcg/0.5ml
- 4.1.2 10mcg/ml
- 4.2 Global Hepatitis B Vaccine (Recombinant) Sales by Type
- 4.2.1 Global Hepatitis B Vaccine (Recombinant) Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Hepatitis B Vaccine (Recombinant) Sales by Type (2021-2032)
- 4.2.3 Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Type (2021-2032)
- 4.3 Global Hepatitis B Vaccine (Recombinant) Revenue by Type
- 4.3.1 Global Hepatitis B Vaccine (Recombinant) Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Hepatitis B Vaccine (Recombinant) Revenue by Type (2021-2032)
- 4.3.3 Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Type (2021-2032)
5 Hepatitis B Vaccine (Recombinant) Market by Application
- 5.1 Hepatitis B Vaccine (Recombinant) Application Introduction
- 5.1.1 Newborn
- 5.1.2 Adult
- 5.2 Global Hepatitis B Vaccine (Recombinant) Sales by Application
- 5.2.1 Global Hepatitis B Vaccine (Recombinant) Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Hepatitis B Vaccine (Recombinant) Sales by Application (2021-2032)
- 5.2.3 Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Application (2021-2032)
- 5.3 Global Hepatitis B Vaccine (Recombinant) Revenue by Application
- 5.3.1 Global Hepatitis B Vaccine (Recombinant) Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Hepatitis B Vaccine (Recombinant) Revenue by Application (2021-2032)
- 5.3.3 Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Application (2021-2032)
6 Global Hepatitis B Vaccine (Recombinant) Sales by Region
- 6.1 Global Hepatitis B Vaccine (Recombinant) Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Hepatitis B Vaccine (Recombinant) Sales by Region (2021-2032)
- 6.2.1 Global Hepatitis B Vaccine (Recombinant) Sales by Region (2021-2026)
- 6.2.2 Global Hepatitis B Vaccine (Recombinant) Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Hepatitis B Vaccine (Recombinant) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Hepatitis B Vaccine (Recombinant) Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Hepatitis B Vaccine (Recombinant) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Hepatitis B Vaccine (Recombinant) Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Hepatitis B Vaccine (Recombinant) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Hepatitis B Vaccine (Recombinant) Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Hepatitis B Vaccine (Recombinant) Revenue by Region
- 7.1 Global Hepatitis B Vaccine (Recombinant) Revenue by Region
- 7.1.1 Global Hepatitis B Vaccine (Recombinant) Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Hepatitis B Vaccine (Recombinant) Revenue by Region (2021-2026)
- 7.1.3 Global Hepatitis B Vaccine (Recombinant) Revenue by Region (2027-2032)
- 7.1.4 Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Hepatitis B Vaccine (Recombinant) Revenue (2021-2032)
- 7.2.2 North America Hepatitis B Vaccine (Recombinant) Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Hepatitis B Vaccine (Recombinant) Revenue (2021-2032)
- 7.3.2 Europe Hepatitis B Vaccine (Recombinant) Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Hepatitis B Vaccine (Recombinant) Revenue (2021-2032)
- 7.4.2 Asia-Pacific Hepatitis B Vaccine (Recombinant) Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Hepatitis B Vaccine (Recombinant) Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Hepatitis B Vaccine (Recombinant) Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 GSK
- 8.1.1 GSK Company Information
- 8.1.2 GSK Business Overview
- 8.1.3 GSK Hepatitis B Vaccine (Recombinant) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 GSK Hepatitis B Vaccine (Recombinant) Product Portfolio
- 8.1.5 GSK Recent Developments
- 8.2 Shenzhen Kangtai Biological Products
- 8.2.1 Shenzhen Kangtai Biological Products Company Information
- 8.2.2 Shenzhen Kangtai Biological Products Business Overview
- 8.2.3 Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) Product Portfolio
- 8.2.5 Shenzhen Kangtai Biological Products Recent Developments
- 8.3 Merck
- 8.3.1 Merck Company Information
- 8.3.2 Merck Business Overview
- 8.3.3 Merck Hepatitis B Vaccine (Recombinant) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Merck Hepatitis B Vaccine (Recombinant) Product Portfolio
- 8.3.5 Merck Recent Developments
- 8.4 Serum Institute
- 8.4.1 Serum Institute Company Information
- 8.4.2 Serum Institute Business Overview
- 8.4.3 Serum Institute Hepatitis B Vaccine (Recombinant) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Serum Institute Hepatitis B Vaccine (Recombinant) Product Portfolio
- 8.4.5 Serum Institute Recent Developments
- 8.5 Sanofi Pasteur
- 8.5.1 Sanofi Pasteur Company Information
- 8.5.2 Sanofi Pasteur Business Overview
- 8.5.3 Sanofi Pasteur Hepatitis B Vaccine (Recombinant) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Sanofi Pasteur Hepatitis B Vaccine (Recombinant) Product Portfolio
- 8.5.5 Sanofi Pasteur Recent Developments
- 8.6 LG Life Sciences
- 8.6.1 LG Life Sciences Company Information
- 8.6.2 LG Life Sciences Business Overview
- 8.6.3 LG Life Sciences Hepatitis B Vaccine (Recombinant) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 LG Life Sciences Hepatitis B Vaccine (Recombinant) Product Portfolio
- 8.6.5 LG Life Sciences Recent Developments
- 8.7 KM Biologics
- 8.7.1 KM Biologics Company Information
- 8.7.2 KM Biologics Business Overview
- 8.7.3 KM Biologics Hepatitis B Vaccine (Recombinant) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 KM Biologics Hepatitis B Vaccine (Recombinant) Product Portfolio
- 8.7.5 KM Biologics Recent Developments
- 8.8 Dynavax Technologies
- 8.8.1 Dynavax Technologies Company Information
- 8.8.2 Dynavax Technologies Business Overview
- 8.8.3 Dynavax Technologies Hepatitis B Vaccine (Recombinant) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Dynavax Technologies Hepatitis B Vaccine (Recombinant) Product Portfolio
- 8.8.5 Dynavax Technologies Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Hepatitis B Vaccine (Recombinant) Value Chain Analysis
- 9.1.1 Hepatitis B Vaccine (Recombinant) Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Hepatitis B Vaccine (Recombinant) Production Mode & Process
- 9.2 Hepatitis B Vaccine (Recombinant) Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Hepatitis B Vaccine (Recombinant) Distributors
- 9.2.3 Hepatitis B Vaccine (Recombinant) Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst